华纳药厂表示，公司于2025年3月向国家药品监督管理局递交该产品的上市许可申请并获得受理。经审 慎研究，结合研发策略，公司决定主动撤回本次药品注册申请。该药品注册申请的主动撤回并终止不会 对公司当期及未来生产经营与业绩产生重大影响。 北京商报讯（记者 丁宁）1月27日晚间，华纳药厂（688799）发布公告称，公司收到国家药品监督管理 局核准签发的《药品注册申请终止通知书》，同意公司撤回利多卡因凝胶贴膏的注册申请。 公告显示，利多卡因凝胶贴膏主要用于缓解带状疱疹后遗神经痛，用于无破损皮肤。 ...

每经AI快讯，1月27日，华纳药厂(688799.SH)公告称，公司收到国家药品监督管理局核准签发的《药品 注册申请终止通知书》，同意公司撤回利多卡因凝胶贴膏的注册申请。该产品主要用于缓解带状疱疹后 遗神经痛，用于无破损皮肤。公司于2025年3月向国家药品监督管理局递交该产品的上市许可申请并获 得受理，但经审慎研究，结合研发策略，公司决定主动撤回本次药品注册申请。该药品注册申请的主动 撤回并终止不会对公司当期及未来生产经营与业绩产生重大影响。 ...

Core Insights - The All-China Federation of Trade Unions has announced the list of national model worker and craftsman innovation studios for 2025, with six studios from the Economic Development Zone being recognized, leading the city in the number of selections [1] - These studios focus on key industries such as new generation information technology, biotechnology, health, robotics, and intelligent manufacturing, aligning with the strategic needs of international technological innovation and high-end industry development [1] - The studios aim to support the development of core technologies, enhance the modernization of industrial chains, and foster talent cultivation through the demonstration and leadership of model workers and craftsmen [1] Group 1: Studio Highlights - **Shang Xiaoli Innovation Studio**: Established in 2021, focuses on rapid skill enhancement and long-term talent development, addressing product quality, production efficiency, and manufacturing costs [3] - **He Maodong Innovation Studio**: Founded in 2018, specializes in the research and design of high-end temperature control equipment for integrated circuit manufacturing, aiming to achieve domestic production and application [5] - **Liu Fang Innovation Studio**: Established in 2019, concentrates on the technological research of aerospace electronic products and intelligent manufacturing, enhancing production quality and efficiency [7] Group 2: Additional Studios - **Luo Ying Innovation Studio**: Founded in 2019, focuses on optical and intelligent technology in military manufacturing, achieving multiple technological breakthroughs [9] - **Shi Xiaogang Innovation Studio**: Established in 2015, dedicated to the research and industrialization of augmented reality (AR) technologies, with applications across various sectors [11] - **Zhao Yanping Innovation Studio**: Founded in 2010, specializes in innovative drug formulation research, with several products approved for market [13] Group 3: Development and Future Plans - The Economic Development Zone Trade Union has prioritized the establishment of innovation studios, having recognized a total of 136 district-level studios, with 35 at the city level and 13 as exemplary studios [14] - The recognition of these six studios underscores the Economic Development Zone's strengths in high-end manufacturing and technological innovation [14] - Future plans include deepening the innovation studio system, enhancing policy collaboration, and promoting the transformation of innovative results into productive forces [14]

Group 1: Product Matrix and Market Position - The company has established a clear and advantageous external product matrix, with significant exclusive and medical insurance advantages in key varieties. Approved products include: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Anti-inflammatory Pain Relief Patch, Lidocaine Gel Patch, Strong Waist and Bone Strengthening Patch, and Daiwen Moxibustion Patch [2] - The Ketoprofen Gel Patch is a key exclusive product with significant market competitiveness, while the Daiwen Moxibustion Patch holds both traditional Chinese medicine exclusivity and medical insurance exclusivity, showcasing distinct advantages [2] Group 2: Brand Development Strategies - The company has implemented a series of systematic and innovative measures to enhance brand influence and market recognition, including expanding into retail pharmacies and online platforms [3] - A brand upgrade event was held on December 6, 2025, introducing the "JiuDian Pain Relief Expert" symbol and the slogan "Change to JiuDian for Pain Relief Patches," aimed at addressing consumer pain points and enhancing brand communication and market competitiveness [3] Group 3: Sales and Procurement Expectations - The 11th batch of national centralized procurement results will be executed nationwide starting February 2026, with procurement cycles lasting until December 31, 2028 [3] - The company is optimistic about the market prospects for the Ketoprofen Gel Patch, which was approved for listing in 2023 and successfully entered the national medical insurance directory [3] Group 4: Innovation in Drug Development - The company is undergoing a comprehensive transformation towards innovative drug research and development, utilizing a strategy of multiple R&D centers and various drug forms [4] - Two innovation drug R&D centers are being established in central and Yangtze River Delta regions, leveraging local clinical resources and cost advantages [4] - The company is focusing on various tumor and chronic disease indications, employing small molecule drugs, peptide drugs, PDC, and ADC formats [4] Group 5: New Drug Advantages - The newly introduced small molecule pain relief innovative drug YJ2301 is designed to overcome limitations of existing neurogenic pain medications, such as limited efficacy and significant side effects [4] - Clinical pre-research data for YJ2301 shows superior pain relief effects and the potential to address issues like drowsiness and tolerance, providing a new solution for neurogenic pain management [4]

Core Viewpoint - Jichuan Pharmaceutical announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine Gel Patch [2] Group 1 - The announcement was made on the evening of September 16 [2] - The drug registration certificate pertains to Lidocaine Gel Patch, indicating a new product approval [2]

Core Viewpoint - Jichuan Pharmaceutical has received approval for its Lidocaine Gel Patch from the National Medical Products Administration, which may enhance its product portfolio and revenue potential [1] Company Summary - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Lidocaine Gel Patch [1] - As of the latest report, Jichuan Pharmaceutical's market capitalization stands at 23.5 billion yuan [1] Revenue Composition - For the year 2024, Jichuan Pharmaceutical's revenue composition is as follows: - Heat-clearing and detoxifying products: 33.53% - Pediatric products: 28.11% - Digestive products: 14.41% - Other sectors: 9.94% - Respiratory products: 8.13% [1]

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine Gel Patch from the National Medical Products Administration [1] Group 1: Company Information - The company is involved in the pharmaceutical industry, specifically focusing on the development and production of local anesthetics [1] - Lidocaine is classified as an amide-type local anesthetic, which functions by stabilizing the nerve cell membrane through the inhibition of ion channels necessary for nerve impulse generation and conduction [1] Group 2: Regulatory Approval - The approval from the National Medical Products Administration signifies a regulatory milestone for the company, allowing it to market the Lidocaine Gel Patch [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke, has received approval from the National Medical Products Administration for the registration certificate of Lidocaine Gel Patch, which is intended for alleviating postherpetic neuralgia [2] Company Summary - The approval of the Lidocaine Gel Patch is seen as a significant addition to the company's product line, which is expected to positively impact its future development [2] - Currently, there are four companies in China, including Shaanxi Dongke, that have been approved for the Lidocaine Gel Patch [2] Industry Summary - The market development cycle for the newly approved drug may be lengthy and is subject to uncertainties influenced by industry policies and procurement bidding [2]

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., received the drug registration certificate for Lidocaine Gel Patch from the National Medical Products Administration [1] Group 1: Company Information - The drug registration certificate pertains to Lidocaine, an amide local anesthetic that stabilizes nerve cell membranes by inhibiting the ion channels required for nerve impulse generation and conduction [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of Lidocaine Gel Patch, indicating a significant advancement in the company's product portfolio [1] Company Summary - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke, is now authorized to market Lidocaine, an amide-type local anesthetic, which works by stabilizing nerve cell membranes through the inhibition of ion channels necessary for nerve impulse conduction [1]